Anti-colorectal cancer activity of macrostemonoside A mediated by reactive oxygen species

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 825-830

  Wang, Yihui ^a   Tang, Qingchao ^b   Jiang, Shixiong ^a   Li, Mingqi ^a   Wang, Xishan ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Macrostemonoside A; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; MACROSTEMONOSIDE A; REACTIVE OXYGEN METABOLITE; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

ALLIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CELL CYCLE ARREST; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR XENOGRAFT;

ALLIUM MACROSTEMON; MUS MUSCULUS;

AFC; AMINOFLUOROCOUMARIN; COLORECTAL CANCER; MACROSTEMONOSIDE A; MSS.A; N-ACETYLCYSTEINE; NAC; PCNA; PI; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPIDIUM IODIDE; REACTIVE OXYGEN SPECIES; ROS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUGS, CHINESE HERBAL; HUMANS; MICE; MICE, NUDE; REACTIVE OXYGEN SPECIES; SAPONINS; STEROIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888826174     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.148     Document Type: Article

References (28)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63(2013):11-30.
2. Center M.M., Jemal A., Smith R.A., Ward E. Worldwide variations in colorectal cancer. CA Cancer J. Clin. 2009, 59:366-378.
3. Lambert R., Sauvaget C., Sankaranarayanan R. Mass screening for colorectal cancer is not justified in most developing countries. Int. J. Cancer 2009, 125:253-256.
4. Goldberg R.M., Fleming T.R., Tangen C.M., Moertel C.G., Macdonald J.S., Haller D.G., Laurie J.A. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group and the Southwest Oncology Group. Ann. Intern. Med. 1998, 129:27-35.
5. Graham J.S., Cassidy J. Adjuvant therapy in colon cancer. Expert Rev. Anticancer Ther. 2012, 12:99-109.
6. Menck H.R., Jessup J.M., Eyre H.J., Cunningham M.P., Fremgen A., Murphy G.P., Winchester D.P. Clinical highlights from the National Cancer Data Base. CA Cancer J. Clin. 1997, 47(1997):161-170.
7. Adler V., Yin Z., Tew K.D., Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104-6111.
8. Moldovan L., Mythreye K., Goldschmidt-Clermont P.J., Satterwhite L.L. Reactive oxygen species in vascular endothelial cell motility. Roles of NAD(P)H oxidase and Rac1. Cardiovasc. Res. 2006, 71:236-246.
9. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell. Physiol. Biochem. 2001, 11:173-186.
10. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10:1343-1374.
11. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
12. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
13. Kirshner J.R., He S., Balasubramanyam V., Kepros J., Yang C.Y., Zhang M., Du Z., Barsoum J., Bertin J. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 2008, 7:2319-2327.
14. Zhang Y., Talalay P. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res. 1994, 54:1976s-1981s.
15. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine. J. Biol. Chem. 1979, 254:7558-7560.
16. Koehn F.E., Carter G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4:206-220.
17. Mishra B.B., Tiwari V.K. Natural products: an evolving role in future drug discovery. Eur. J. Med. Chem. 2011, 46:4769-4807.
18. Peng J.P., Wu Y., Yao X.S., Okuyama T., Narui T. Two new steroidal saponins from Allium macrostemon. Yao Xue Xue Bao 1992, 27:918-922.
19. Zhou H., Yang X., Wang N.L., Zhang Y.O., Cai G.P. Macrostemonoside A promotes visfatin expression in 3T3-L1 cells. Biol. Pharm. Bull. 2007, 30:279-283.
20. Xie W., Zhang Y., Wang N., Zhou H., Du L., Ma X., Shi X., Cai G. Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia and visceral obesity in high-fat diet-fed C57BL/6 mice. Eur. J. Pharmacol. 2008, 599:159-165.
21. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol. Ther. 2008, 7:1875-1884.
22. Shao Y., Chin C.K., Ho C.T., Ma W., Garrison S.A., Huang M.T. Anti-tumor activity of the crude saponins obtained from asparagus. Cancer Lett. 1996, 104:31-36.
23. Mimaki Y., Kanmoto T., Kuroda M., Sashida Y., Satomi Y., Nishino A., Nishino H. Steroidal saponins from Hosta longipes and their inhibitory activity on tumour promoter-induced phospholipid metabolism of HeLa cells. Phytochemistry 1996, 42:1065-1070.
24. Ghosh P., Besra S.E., Tripathi G., Mitra S., Vedasiromoni J.R. Cytotoxic and apoptogenic effect of tea (Camellia sinensis var. assamica) root extract (TRE) and two of its steroidal saponins TS1 and TS2 on human leukemic cell lines K562 and U937 and on cells of CML and all patients. Leuk. Res. 2006, 30:459-468.
25. Vargas A.J., Thompson P.A. Diet and nutrient factors in colorectal cancer risk. Nutr. Clin. Pract. 2012, 27:613-623.
26. Komninou D., Ayonote A., Richie J.P., Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood) 2003, 228:396-405.
27. Tseng C.H. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur. J. Endocrinol. 2012, 167:409-416.
28. Aljada A., Mousa S.A. Metformin and neoplasia: implications and indications. Pharmacol. Ther. 2012, 133:108-115.